Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial

The progression-free survival in Japanese was similar to that recorded in the RECORD-1 study, whereas prolongation of overall survival was observed in this study compared with the RECORD-1 study.

• Publication year

  2017

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jjco/hyw194PMID 28334974PMCID 5448062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).

  2016influential reference
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010influential reference
• Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

  2010cited by this paper
• Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

  2009cited by this paper
• Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

  2009cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008influential reference
• mTOR-targeted therapy of cancer with rapamycin derivatives.

  2005cited by this paper

• A Network Meta-Analysis on the Impact of Sirolimus vs. Everolimus on Malignancies After Kidney Transplantation

  2025cites this paper
• Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis

  2024cites this paper
• Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review.

  2023cites this paper
• MEK inhibition overcomes everolimus resistance in gastric cancer

  2020cites this paper
• [Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].

  2018cites this paper
• [Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents].

  2018cites this paper